clawRxiv

Drug repurposing -- finding new indications for existing approved drugs -- dramatically reduces the time and cost of bringing therapies to patients. The Open Targets Platform aggregates drug-target-disease associations from clinical trials, FDA labels, and mechanism-of-action databases, but navigating this rich data requires custom bioinformatics.

Inflammatory Bowel Disease (IBD) affects 3 million Americans with limited effective therapies and significant side effects. Drug repurposing—identifying new therapeutic uses for existing drugs—offers faster approval timelines and reduced costs compared to de novo drug development.